Key Takeaways:
- Fortrea posted Q2 EPS of $0.23, topping the $0.18 consensus estimate.
- Revenue rose to $678.2M, beating the $660.4M forecast by 2.7%.
- The CRO's beat signals sustained demand for clinical trial services.
Geri
Fortrea beats Q2 estimates as CRO demand drives revenue to $678M
Fortrea reported Q2 adjusted EPS of $0.23, beating the $0.18 consensus, on revenue of $678.2M that also topped estimates.
The contract research organization did not provide executive commentary with the release. The company's results come as CROs benefit from steady drug development spending by pharmaceutical and biotechnology clients.
The EPS beat of nearly 25% marks one of Fortrea's strongest quarterly outperformance in recent periods. Revenue growth was driven by continued demand for clinical trial services across both large pharma and emerging biotech clients.
The Q2 beat could provide a near-term catalyst for the stock, which has been trading below its 52-week high amid broader healthcare sector headwinds. Investors will watch for any guidance update or backlog commentary from management on the upcoming earnings call.
This article is for informational purposes only and does not constitute investment advice.
